Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate
Therapeutic Advances in Musculoskeletal Disease
Published online on May 28, 2026
Abstract
Therapeutic Advances in Musculoskeletal Disease, Volume 18, January-December 2026.
Background:The relationship between biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and the incidence of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) remains unclear.Objective:To investigate ...
Background:The relationship between biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and the incidence of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) remains unclear.Objective:To investigate ...